Greenland Mines Ltd. (GRML)
GRML trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | GRML on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | 2022 |
| SEC CIK | 0001907223 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
Financials
Not reported in SEC XBRL data.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "Without additional funding, there is substantial doubt about the Company's ability to continue as a going concern for twelve months from the date these financial statements are issued." | 10-Q 2026-08-17 |
| Cash and burn | $9.3M cash; operating cash flow -$3.6M a quarter. | Report 2026-06-30 |
| Shares outstanding | No cover-page share count in XBRL | Cover page 2026-08-17 |
| Reverse splits, 3 years | 1; latest 1-for-50 on 2026-08-24 | Source 2026-08-24 |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 6 424B5 takedowns, 5 at the market | Latest 2026-09-28 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | BCRG Group, Irvine, California, United States; changed auditors 2 times in 24 months | 8-K 4.01 2026-07-08 |
| Late filings, 12 months | 3 NT notices | NT 10-Q 2026-08-14 |
| Insider trades, 12 months | Bought $468K, sold $40K on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q2 2026 2026-06-30 | Not filed | -$3.7M | -$6.9M | $9.3M | No debt tags | Needs four quarters | 10-Q 2026-08-17 |
| Q1 2026 2026-03-31 | Not filed | -$13.9M | -$5.0M | $10.0M | No debt tags | Needs four quarters | 10-Q 2026-08-17 |
| Q4 2025 2025-12-31 | Not filed | -$1.3M | -$1.3M | $7.2M | No debt tags | Needs four quarters | 10-K/A 2026-08-14 |
| Q3 2025 2025-09-30 | Not filed | -$2.9M | -$1.1M | $7.3M | No debt tags | Needs four quarters | 10-Q 2025-11-13 |
| Q2 2025 2025-06-30 | Not filed | -$4.1M | -$1.9M | $8.4M | No debt tags | Needs four quarters | 10-Q 2026-08-17 |
| Q1 2025 2025-03-31 | Not filed | -$2.2M | -$1.6M | $566K | $1.8M | Needs four quarters | 10-Q 2026-08-17 |
| Q4 2024 2024-12-31 | Not filed | -$2.1M | -$944K | $64K | $241K | Needs four quarters | 10-K/A 2026-08-14 |
| Q3 2024 2024-09-30 | Not filed | -$3.0M | -$1.1M | $51K | No debt tags | Needs four quarters | 10-Q 2025-11-13 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document REGISTRATION STATEMENT | S-1 | 2026-10-26 |
| Latest annual report AMENDMENT NO. 1 TO FORM 10-K | 10-K/A | 2026-08-14 |
| Latest quarterly / interim | 10-Q | 2026-11-16 |
| Latest current report CURRENT REPORT | 8-K | 2026-11-12 |
| Latest proxy PROXY STATEMENT | DEF 14A | 2026-06-22 |
Source: SEC EDGAR submissions feed, 272 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -6.0% |
| 1 month | -34.8% |
| 3 months | -64.6% |
| Year to date | -75.0% |
| 1 year | -84.8% |
| From 52-week high | -88.8% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Other listings for this company
| Ticker | Name | Price |
|---|---|---|
| GRMLW | Greenland Mines Ltd Warrant | $0.2801 |
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| ELOX | Eloxx Pharmaceuticals Inc. | $12.75 | -3.04% | $51.5M |
| INKT | MiNK Therapeutics Inc. | $9.35 | +0.11% | $48.0M |
| PMCB | PharmaCyte Biotech Inc. | $5.57 | -16.62% | $59.8M |
| CGTX | Cognition Therapeutics Inc. | $0.6388 | -6.03% | $60.8M |
| OKYO | OKYO Pharma Limited | $1.18 | -12.96% | $61.7M |
| CSBR | Champions Oncology Inc. | $4.68 | -0.53% | $65.1M |
| ATRA | Atara Biotherapeutics Inc. | $6.40 | -16.88% | $65.2M |
| CRDF | Cardiff Oncology Inc. | $0.8477 | +16.75% | $65.9M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier